Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency
27 juin 2022 01h00 HE | Curium
Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...